ALZHEIMER'S DISEASE BLOOD TESTS COULD IMPROVE DIAGNOSIS IN PRIMARY CARE, SPEED RECRUITING FOR RESEARCH & REDUCE WAIT TIMES

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Alzheimer's-Assoc

More Like This

C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

C₂N Diagnostics, LLC Announces Investment From Eisai Inc.

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study

PR Newswire associated0

Diadem Unveils Novel Findings on Early Alzheimer's Disease Detection Using p53-Specific Antibody at CTAD 2024

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey

Alzheimer’s Society and Alzheimer’s Research UK with People’s Postcode Lottery ambassador Matt Johnson and head of charities Laura Chow

£5 million awarded to revolutionise dementia diagnosis